Introduction: the significant causes of mortality among individuals with sickle cell anaemia (SCA) such as acute chest syndrome and cerebrovascular
Introduction
Sickle cell anaemia has been recognized as a problem of major public health significance by the World Health Organization [1] . The highest frequency of the disease is found in tropical regions particularly subSaharan Africa, India and the Middle East. More than 75% of sickle cell anaemia cases occur in sub-Saharan Africa [1] . Nigeria 
Methods

Study area and population
The study was conducted among adult patients with sickle cell anaemia attending the Haematology Clinic of LASUTH, Lagos, Nigeria, while apparently healthy individuals with no known medical condition served as controls. LASUTH is a major tertiary healthcare facility, located in the south-western part of Nigeria, within the Lagos metropolis.
Study design
This was a cross-sectional study.
Study period
The study was carried out over a period of eight months from May 2016 to December 2016.
Sampling technique
Purposive non-probability sampling technique was used to recruit presumably healthy staff and students of LASUTH Ikeja with haemoglobin phenotype AA and they served as the control group. A sampling frame containing the list of individuals with sickle cell anaemia attending the adult Haematology Clinic in LASUTH was drawn and subjects were selected randomly. However, only individuals with a haemoglobin electrophoresis result showing the SS band were enrolled into the study. The inclusion criteria were: age between 18 and above; known patients with sickle cell anaemia (screened by the haemoglobin S solubility test and diagnosed by cellulose acetate electrophoresis at pH 8.6) who are in steady state defined as the period free of crisis extending from at least three weeks since the last clinical event and three months or more since the last blood transfusion, to at least one week before the start of a new clinical event [46] ; haemoglobin AA persons (confirmed by cellulose acetate electrophoresis at pH 8.6) who served as the control group; those who met the above criteria and agreed to participate in the study by signing the informed consent form. The participants were classified as follows:
adults with sickle cell anaemia in steady state; HbAA controls who were age and sex-matched with the adults with sickle cell anaemia.
The exclusion criteria were: confirmed phenotype HbAC, HbAS;
history of acute or chronic illness e.g. any febrile illness, hypertension, diabetes, epilepsy, asthma; intravenous drug users; non consenting participants.
Sample size determination
Sample size was determined using the formula for prevalence study by Daniel [47, 48] .
Where: n = sample size; Z = statistic for a level of confidence of 95%, which is conventional, Z value is 1.96; p = expected prevalence; q = However, in order to accommodate possible attrition or unforeseen errors in completing the study questionnaire or blood sample processing, an additional 10% (9 patients) of the calculated figure was added. Therefore, a total of 192 participants (96 in each group) were recruited into this study.
Ethical consideration and clearance
Ethical approval was obtained from the Health Research and Ethics
Committee of LASUTH prior to commencement of the study.
Participants' informed consent
A written informed consent was obtained from all the participants before being recruited into the study. No participant was in any way coerced or cajoled to participate in this study. Study was done at no cost to the participants.
Confidentiality
The names and initials of all participants were not recorded or used to guarantee confidentiality. Participants were instead given code numbers. Paper records were secured in a cabinet inside a secured room. Electronic data was protected using a password known only to the researchers.
Questionnaire administration and history taking
Each participant was interviewed to obtain relevant demographic and clinical data with the use of a questionnaire. The questionnaire was administered to each participant by a member of the research team.
Information on the HbSS subjects and their medical history including disease complications were retrieved from their case notes.
Specimen collection and storage
Seven milliliters of venous blood was drawn from each subject. Five milliliters of this was dispensed into sodium ethylene diamine tetraacetate (EDTA) specimen bottles. This sample was used for a full blood count (FBC). This was analyzed within 2 hours of collection.
Some of the blood collected in the EDTA specimen bottle was used for cellulose acetate electrophoresis test. The remaining two milliliters of the blood was dispensed into another set of EDTA bottles. These samples were prepared for DNA extraction and subsequently used for genetic analysis. The samples were washed with phosphate buffer saline (PBS) until the supernatant was white. The samples were then stored at the appropriate temperature till the DNA extraction was done. It was stored at 2-8°C if the DNA extraction was scheduled to be done within a week, at -20°C within a month and -80°C for a longer period of time.
Statistical analysis
All data obtained were entered into and analyzed using Statistical respectively. The differences in mean distribution of variables were tested using student t-test or ANOVA where appropriate (significant level was set at p < 0.05 or F < 0.05 for student t-test and ANOVA respectively). The degree of association between variables were evaluated with chi-square test and significance was set at p < 0.05. (Table 1) .
Results
Age and gender
Prevalence of MTHFR C677T and A1298C mutations
The overall prevalence of the C677T mutation among participants was 19.3% (37 of 192), while prevalence of A1298C was 15% (29 of 192) ( Figure 1, Figure 2 ). The genotype frequencies for homozygous dominant (MTHFR 677CC), heterozygous dominant (MTHFR 677CT) and homozygous recessive (MTHFR 677TT) genes among the cases were 83.3%, 15.6% and 1% respectively. In the controls, genotype frequency was 78.1% for the homozygous dominant (CC) and 21.9%
for the heterozygous dominant (CT). The homozygous recessive (TT) genotype was not detected among the controls in this study (Table 2) .
Similarly, the genotype frequencies of the A1298C mutation amongst the cases for the homozygous dominant (AA), heterozygous dominant (AC) and homozygous recessive (CC) were 84.4%, 14.6% and 1%
respectively. However, in the controls, genotype frequencies were 85.4% for the homozygous dominant (AA), 12.5% for the heterozygous dominant (AC) and 2.1% for homozygous recessive (CC) genotype (Table 2) .
MTHFR C677T and A1298C allelic frequency distribution
The relative frequencies of the 677T alleles for the cases and controls were 8.9% and 10.9% respectively while that of the 1298C alleles was 8.3% in both groups (Table 3) .
Ages and genders of participants with C677T and A1298C mutations
Both mutations in the two groups were not statistically significant when correlated with the ages and genders of the participants except age vs A1298C in controls which was statistically significant (Table 4) .
Discussion
Studies have shown that MTHFR gene mutation results in the diminished activity of the MTHFR enzyme which is crucial in folate metabolism [26, 39] . Polymorphisms of the MTHFR gene in persons with sickle cell anaemia have been suggested as a potential risk for vaso-occlusive events [37, 39] . MTHFR mutations have also been implicated as a probable risk factor for avascular necrosis in sickle cell anaemia [43, 45] . Several genetic factors contribute to the phenotypic expression of individuals with sickle cell anaemia. The MTHFR gene mutations C677T and A1298C are some of such genetic polymorphisms which have been implicated as genetic modifiers of the disease. The prevalence of the C677T mutation among the subjects with HbSS was 16.6% and 21.9% in HbAA controls, showing no statistical difference. Likewise, the prevalence of the A1298C mutation was 15.6% in the cases and 1% lower in the control group.
The population frequency of the A1298C allele is less documented than that of the C677T allele and there is inadequately published data about the prevalence of these mutations among Nigerians. These results were higher than a reported prevalence of 5% found in a study of African blacks [51] , 9% in another research among African
American individuals with sickle cell anaemia [52] and 12% described among Brazilian blacks [51] . However, it is comparable to a study done among a group of African American adults with sickle cell anaemia which reported a prevalence of 15% for the C677T Africans from four tribes in sub-Saharan Africa, the frequency of the homozygous recessive TT genotype was also not reported. The frequency of the TT genotype among Blacks living outside Africa was also noted to be low [51] . This conflicts with a frequency of TT genotype ranging from 8% among Germans, 18% among Italians and 10-14% among whites living outside Europe to about 21% in Hispanics. These estimates suggest that the homozygous recessive TT variant is less common in Africans than in some other populations.
Regarding the A1298C mutation, the homozygous recessive (CC) genotype frequency was 1% in cases and 2.1% in the controls which was not found to be statistically significant. This differs from a CC variant frequency of 6% seen in a survey carried out on 117 healthy
Portuguese Caucasians [57] . The 6777T allele frequency ranged from 8.9% in the cases to 10.9% among the controls. This is in keeping with a prevalence of 12% in a study done among Blacks in Brazil [24] and 10% in another one carried out among Blacks in Georgia in the United States of America [24] . However, it was slightly higher than a prevalence of 6.3% generated from a pooled data on Africans in 
Conclusion
The prevalence of MTHFR C677T was higher than A1298C mutations among sickle cell anaemia subjects. This research was self-funded, and cost was a major limiting factor. A larger study using more than 96 HbSS and 96 HbAA could be more representative of the aims and objectives of this study.
What is known about this topic
• MTHFR gene mutation reduces the activity of the MTHFR enzyme and thus leads to hyperhomocysteinaemia;
• This is particularly heightened in patients with sickle cell anaemia who have an increased demand for folate due to their high red cell turnover or shortened red cell lifespan;
• Hyperhomocysteinaemia has been implicated with a number of complications in sickle cell anaemia including avascular necrosis of the femur head, acute chest syndrome etc.
What this study adds
• The prevalence of MTHFR C677T is higher than A1298C mutations among sickle cell anaemia subjects in Lagos, Nigeria. 
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